Orange Sa (EOG5) News

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in...

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with...

Form 8-K - Current report

Form 8-K - Current report

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc...

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Issues Letter to Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues...

ProMIS Neurosciences, Inc. Announces Leadership Transition

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc...

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential...